Asian outpatients with schizophrenia: A double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol

Journal of the Medical Association of Thailand

Volumn 89, Issue 8, 2006, Pages 1157-1170

  Kongsakon, Ronnachai ^a   Trinidad Oate, Pureza ^b   Chaudhry, Haroon Rashid ^c   Raza, Syed Baqar ^d   Leynes, Cynthia R ^e   Khan, Inam Ur Rehman ^f   Ismail, Hasanah Che ^g   Chan, Benjamin ^h   Ignacio, Joy C ⁱ   Rodriguez, Sonia C ^e   Lowry, Amanda J ^j   Brnabic, Alan J M ^j   Buenaventura, Robert ^k  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Cebu Doctors Hospital   (Philippines)

^c FATIMA JINNAH MEDICAL COLLEGE   (Pakistan)

^d General Hospital   (Pakistan)

^e ST LUKE S MEDICAL CENTER   (Philippines)

^f Sind Social Security Institution   (Pakistan)

^g SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^h Hospital Permai   (Malaysia)

ⁱ Jose R Reyes Memorial Medical Center   (Philippines)

^j ELI LILLY AUSTRALIA PTY LTD   (Australia)

^k Eli Lilly (Philippines) Inc   (Philippines)

more..

Author keywords

Antipsychotic; Asia; Haloperidol; Olanzapine; Quality of life; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PRESCRIPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33748518379     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. World Health Organization. The world health report 2001. Mental health: New understanding, new hope. Geneva: World Health Organization; 2001.
2. The Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998; 43(Suppl 2): 25S-40S.
3. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30: 193-217.
4. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999; 60: 649-57.
5. Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opin Investig Drugs 2001; 2: 110-7.
6. Awad AG, Voruganti LN. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull 2000; 26: 557-64.
7. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.
8. Dossenbach M, Erol A, el Mahfoud KM, Shaheen MO, Sunbol MM, Boland J, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004; 65: 312-21.
9. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125-37.
10. Gomez JC, Crawford AM. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry 2001; 62(Suppl 2): 6-11.
11. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63(Suppl 4): 56-62.
12. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466-74.
13. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98.
14. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998; 28: 551-8.
15. Saxena S, Carlson D, Billington R. The WHO quality of life assessment instrument (WHOQOL-Bref): the importance of its items for cross-cultural research. Qual Life Res 2001; 10: 711-21.
16. Hasanah CI, Naing L, Rahman AR. World Health Organization Quality of Life Assessment: brief version in Bahasa Malaysia. Med J Malaysia 2003; 58: 79-88.
17. Heinze M, Taylor RE, Priebe S, Thornicroft G. The quality of life of patients with paranoid schizophrenia in London and Berlin. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 292-7.
18. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112-7.
19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
20. National Institute of Mental Health. Clinical Global Impressions (CGI). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. rev. ed. Rockville, MD: US Department of Health, Education, and Welfare, NIMH; 1976: 217-22.
21. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
22. National Institute of Mental Health. Clinical Global Impressions (CGI). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. rev. ed. Rockville, MD: US Department of Health, Education, and Welfare, NIMH; 1976: 534-7.
23. Simpson GM, Angus JW. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9.
24. Kaur M. War on FAT. World Health Organization. 2001. Available at: http://www.who.int/archives/world-health-day/news_articles.en. shtml#War%20on%20FAT Accessed 21 August 2003.
25. World Health Organization. Redefining obesity and its treatment. Manila: Regional Office for the Western Pacific, World Health Organization; 2000.
26. Eli Lilly and Company. Zyprexa□ Olanzapine Tablets. 2005. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf Accessed 11 October 2004.
27. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001; 9: 89-104.
28. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65.
29. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-6.
30. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154: 1-63.
31. th ed. Philippines: National Center for Mental Health; 2004.
32. MIMS (Malaysia). Haloperidol.
33. Herrman H, Hawthorne G, Thomas R. Quality of life assessment in people living with psychosis. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 510-8.
34. Voruganti L, Heslegrave R, Awad AG, Seeman MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28: 165-72.
35. Pinikahana J, Happell B, Hope J, Keks NA. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs 2002; 11: 103-11.
36. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26: 25-40.
37. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999; 8: 417-26.
38. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998; 18: 41-9.
39. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693-702.
40. Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, et al. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 2001; 21: 375-81.
41. Ungvari GS, Chung YG, Chee YK, Fung-Shing N, Kwong TW, Chiu HF. The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999. Br J Clin Pharmacol 2002; 54: 437-44.
42. Moore S, Jaime LK, Maharajh H, Ramtahal I, Reid S, Ramsewak FS, et al. The prescribing of psychotropic drugs in mental health services in Trinidad. Rev Panam Salud Publica 2002; 12: 207-14.
43. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205-11.
44. Chong SA, Sachdev P, Mahendran R, Chua HC. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust N Z J Psychiatry 2000; 34: 988-91.
45. Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996; 32: 253-7.
46. Meltzer HY, Kostakoglu AE. Combining antipsychotics: is there evidence for efficacy? Psychiatric Times 2000; 17: 25-32.